FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease – labiotech (press release) (blog)
labiotech (press release) (blog) |
FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease
labiotech (press release) (blog) Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form … Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and morePMLiVE Orchard Therapeutics Receives Rare Pediatric Disease Designation for MLD TherapyRare Disease Report Orchard Therapeutics’ OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of …Markets Insider The Pharma Letter all 4 news articles » |
Tampa Bay Business Journal |
New HQ puts Tampa immunotherapy company in Moffitt’s backyard
Tampa Bay Business Journal Morphogenesis is developing targeted immunotherapies, or treatments that use the body’s own immune system to fight cancer. Many immunotherapies are personalized, or developed for each patient’s specific genetics, and can run into the hundreds of … |
Tampa Bay Business Journal |
New HQ puts Tampa immunotherapy company in Moffitt’s backyard
Tampa Bay Business Journal Morphogenesis is developing targeted immunotherapies, or treatments that use the body’s own immune system to fight cancer. Many immunotherapies are personalized, or developed for each patient’s specific genetics, and can run into the hundreds of … |
Drug Target Review |
T cell populations in CLL patients indicate potential success of CAR T cell therapy
Drug Target Review These healthier ‘early memory’ T cells were marked by the expression of CD8 and CD27, as well as the absence of CD45RO. The findings show the potential to improve responses by enhancing a patient’s immune cells with emerging cell manufacturing … |